Originally published by our sister publication Pain Medicine News
A recent study has shown that atogepant (Qulipta, AbbVie), may help prevent migraines in people who have had no success with other preventive drugs. The study, presented at the 2023 annual meeting of the American Academy of Neurology (abstract 19), involved people with episodic migraine, which is defined as up to 14 headache days per month with migraine characteristics.
Atogepant, an oral medication, is a calcitonin